Rossari Current Deferred Revenue from 2010 to 2024

ROSSARI Stock   826.15  18.40  2.18%   
Rossari Biotech's Current Deferred Revenue is increasing with slightly volatile movements from year to year. Current Deferred Revenue is predicted to flatten to about 118.8 M. Current Deferred Revenue is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. View All Fundamentals
 
Current Deferred Revenue  
First Reported
2010-12-31
Previous Quarter
125.1 M
Current Value
118.8 M
Quarterly Volatility
380.8 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Rossari Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rossari Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 320 M, Interest Expense of 203.4 M or Total Revenue of 10 B, as well as many indicators such as . Rossari financial statements analysis is a perfect complement when working with Rossari Biotech Valuation or Volatility modules.
  
This module can also supplement various Rossari Biotech Technical models . Check out the analysis of Rossari Biotech Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Rossari Stock

Rossari Biotech financial ratios help investors to determine whether Rossari Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Rossari with respect to the benefits of owning Rossari Biotech security.